Division of Cardiology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Division of Cardiology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Korean J Intern Med. 2020 May;35(3):498-513. doi: 10.3904/kjim.2020.105. Epub 2020 Apr 29.
Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.
心力衰竭（HF）是全球老龄化社会日益关注的健康问题。沙库巴曲缬沙坦正在改变 HF 全谱的真实世界治疗方法。这始于 2014 年发表的 PARADIGM-HF 试验，该试验表明抑制利钠肽分解并与抑制 HF 患者的肾素-血管紧张素系统相结合，对射血分数降低的患者具有有益的效果。随后的大规模随机试验评估了血管紧张素受体-脑啡肽酶抑制剂在急性失代偿或射血分数保留的 HF 患者中的作用。事后分析也在进行中。本综述基于随机对照试验及其相关研究，总结了沙库巴曲缬沙坦在以患者为中心的结局方面的最新证据。
